Skip to main content

Table 5 Adverse events in the safety population (n = 492)

From: Clinical characteristics of middle-aged and older patients with MS treated with interferon beta-1b: post-hoc analysis of a 2-year, prospective, international, observational study

  Number (%) of patients with AEs
  Aged 41–50 years (n = 334) Aged > 50 years (n = 158)
Any AE 50 (15 %) 31 (19.6 %)
Any MS-related AE 22 (6.6 %) 4 (2.5 %)
Any severe AE 11 (3.3 %) 6 (3.8 %)
Any serious AE 14 (4.2 %) 2 (1.3 %)
Any AE related to study drug 32 (9.6 %) 21 (13.3 %)
Any serious AE related to study drug 4 (1.2 %) 0 (0.0 %)
Deaths 3 (0.9 %) 2 (1.3 %)
Deaths related to study drug 0 (0.0 %) 0 (0.0 %)
  1. AE adverse event